Your shopping cart is currently empty

BBO-8520 is a first-in-class, direct dual inhibitor of both the active (ON) and inactive (OFF) conformational states of KRASG12C. BBO-8520 binds to the Switch-II/Helix3 pocket of KRASG12C, covalently modifying the target cysteine residue and thereby disabling effector binding in the ON state. BBO-8520 exhibits potent inhibition of KRAS signaling under growth factor-activated conditions, where existing OFF-only inhibitors demonstrate minimal activity. In vivo, BBO-8520 rapidly engages its target and suppresses signaling, resulting in durable tumor regression across multiple models, including those resistant to OFF-only KRASG12C inhibitors.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $424 | - | In Stock | |
| 5 mg | $1,060 | - | In Stock | |
| 10 mg | $1,700 | - | In Stock | |
| 25 mg | $3,400 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $1,700 | - | In Stock |
| Description | BBO-8520 is a first-in-class, direct dual inhibitor of both the active (ON) and inactive (OFF) conformational states of KRASG12C. BBO-8520 binds to the Switch-II/Helix3 pocket of KRASG12C, covalently modifying the target cysteine residue and thereby disabling effector binding in the ON state. BBO-8520 exhibits potent inhibition of KRAS signaling under growth factor-activated conditions, where existing OFF-only inhibitors demonstrate minimal activity. In vivo, BBO-8520 rapidly engages its target and suppresses signaling, resulting in durable tumor regression across multiple models, including those resistant to OFF-only KRASG12C inhibitors. |
| In vivo | BBO-8520 (10 mg/kg/d; po) inhibits pERK and KRAS G12C activation in the KrasG12C-p53 driven GEMM model, resulting in sustained tumor regression. Additionally, BBO-8520 demonstrates a strong dose- and time-dependent pharmacodynamic effect in KRASG12C mutant tumor-bearing mice, with pERK inhibition exceeding 80% [1]. |
| Synonyms | BBO8520 |
| Molecular Weight | 729.74 |
| Formula | C35H33F6N7O2S |
| Cas No. | 2893809-51-1 |
| Smiles | N#CC1=C(SC2=C(F)C=CC(=C12)C=3C(F)=C4N=C(N=C(C4=CC3C(F)(F)F)N5CC(N(C(=O)C=C)CC5C)C)OCC67N(CCC6)CC(F)C7)N |
| Color | White |
| Appearance | Solid |
| Storage | keep away from direct sunlight,store under nitrogen,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO: ≥ 40 mg/mL, Sonication is recommended. |
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.74 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.